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Objectives
Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized controlled
trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in
heterogeneous real-world settings are limited.
Methods
The study design was an international multicohort collaboration. Logistic regression was used to
compare virological and immunological outcomes at 12  3 months after starting ART with an
integrase strand transfer inhibitor (INSTI), contemporary nonnucleoside reverse transcriptase
inhibitor (NNRTI) or boosted protease inhibitor (PI/b) with two nucleos(t)ides after 1 January 2012.
The composite treatment outcome (cTO) defined success as VL < 200 HIV-1 RNA copies/mL with
no regimen change and no AIDS/death events. Immunological success was defined as a CD4 count
> 750 cells/lL or a 33% increase where the baseline CD4 count was ≥ 500 cells/lL. Poisson
regression compared clinical failures (AIDS/death ≥ 14 days after starting ART). Interactions
between ART class and age, CD4 count, and VL were determined for each endpoint.
Results
Of 5198 ART-na€ıve persons in the International Cohort Consortium of Infectious Diseases
(RESPOND), 45.4% started INSTIs, 26.0% PI/b and 28.7% NNRTIs; 880 (17.4%) were aged >
50 years, 2539 (49.4%) had CD4 counts < 350 cells/lL and 1891 (36.8%) had VL > 100 000
copies/mL. Differences in virological and immunological success and clinical failure among ART
classes were similar across age groups (≤ 40, 40–50 and > 50 years), CD4 count categories (≤ 350
vs. > 350 cells/lL) and VL categories at ART initiation (≤ 100 000 vs. > 100 000 copies/mL), with
all investigated interactions being nonsignificant (P > 0.05).
Conclusions
Differences among ART classes in virological, immunological and clinical outcomes in ART-na€ıve
participants were consistent irrespective of age, immune suppression or VL at ART initiation. While
confounding by indication cannot be excluded, this provides reassuring evidence that such
subpopulations will equally benefit from contemporary ART.
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Randomized clinical trials of antiretroviral therapy (ART)-
na€ıve persons suggest either similar or superior immuno-
logical and virological responses with integrase strand
transfer inhibitor (INSTI)-containing regimens compared
to contemporary boosted protease inhibitors (PI/bs) and
nonnucleoside reverse transcriptase inhibitors (NNRTIs)
[1–7]. There are no adequately powered studies assessing
longer term clinical outcomes with INSTIs. Most random-
ized clinical trials report results within relevant sub-
groups, such as viral load (VL), CD4 count and age
subgroups. In general, such trials report no differences
across these relevant subgroups [2], or small and some-
times nonsignificant differences favouring INSTI-contain-
ing regimens in older persons [6], those with higher
baseline CD4 counts [4,6] or those with higher baseline
VLs [1,4,8]. Smaller differences were reported between an
INSTI (dolutegravir) and an NNRTI (efavirenz) in those
with high VL or low CD4 count or aged > 50 years at
baseline [7]. In contrast, cohort studies lack randomiza-
tion, but they may represent a more real-world setting
for investigating the response to different ART classes
and are often better powered for subgroup comparisons.
Previous cohort studies, including an analysis from the
International Cohort Consortium of Infectious Diseases
(RESPOND), have shown a more favourable virological
and/or immunological response in those starting INSTIs
compared to other ART classes [9–11], but it is not clear
if this finding is consistent across key subpopulations.
The aim of this study was to compare shorter term
virological and immunological outcomes and clinical
events of AIDS/death in ART-na€ıve persons starting ART
in RESPOND with either an INSTI, PI/b or NNRTI regimen
in key subgroups.
Methods
Study design and participants
The International Cohort Consortium of Infectious Dis-
eases (RESPOND) is a collaboration of 17 cohort studies,
including 29 432 HIV-1-positive persons from across
Europe and Australia [12]. Standardized data including
information on demographics, HIV-related factors, ART,
coinfections, comorbidities and various biomarkers are
collected at enrolment and updated annually (details at
https://www.chip.dk/Studies/RESPOND). All cohorts used
the HIV Cohorts Data Exchange Protocol (HICDEP) for
data collection (details at https://hicdep.org/) and deaths
are centrally validated using the Coding of Death in HIV
(CoDe) methodology [13].
Persons aged > 18 years were included in this analysis
if they were ART-na€ıve with a VL > 200 HIV-1 RNA
copies/mL and started exactly three antiretrovirals during
prospective follow-up after 1 January 2012 with either
an INSTI (dolutegravir, elvitegravir, raltegravir or bicte-
gravir), PI/b (darunavir or atazanavir) or NNRTI (efavir-
enz or rilpivirine) and had a CD4 count and VL measured
in the 12 months prior to starting ART (for those without
baseline data, the first CD4 count or VL after starting
ART was used, at most 12 weeks after ART initiation).
Outcomes
Baseline was defined as the date of starting ART. Persons
were stratified a priori according to baseline VL (≤
100 000 or > 100 000 copies/mL), baseline CD4 count (≤
350 or > 350 cells/lL), age (≤ 40, 41–50 or > 50 years)
and presence of severe immunosuppression (CD4
count ≤ 200 cells/lL or clinical AIDS).
Immunological success was defined as a CD4 count
> 750 cells/lL (where the baseline CD4 count was < 500
cells/lL) or a 33% increase in CD4 count (where the base-
line CD4 count was ≥ 500 cells/lL), reflecting the finding
that the incidence of AIDS/death is no longer increased
at CD4 counts > 750 cells/lL [14]. The composite treat-
ment outcome (cTO) defined success as VL < 200 copies/
mL with no regimen change and no AIDS/death events.
Switches in coformulation or change of booster were not
considered to be a regimen change, while switches to a
two-drug regimen or of an individual component, such
as tenofovir disoproxil fumarate (TDF) to tenofovir alafe-
namide (TAF), were considered to be changes as they
may be related to drug toxicity.
A VL < 200 copies/mL was used following consensus
agreement within the RESPOND virological outcomes
working group reflecting cohort differences in lower lim-
its of detection. A window of 3 months was used;
immunological and cTO success was assessed at
12  3 months. Clinical outcome was defined as the first
new AIDS diagnosis or death from any cause occur-
ring > 14 days after baseline.
Statistical methods
Logistic regression was used to assess the odds of cTO
and immunological success, testing the interaction
between ART class and baseline VL, CD4 count, presence
of severe immunosuppression and age. Further analyses
used VL < 50 copies/mL to define cTO success, and an
on-treatment analysis considered only VL < 200 copies/
mL (or 50 copies/mL) among those with data who
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remained on their initial regimen (on-treatment virologi-
cal success). Poisson regression was used to investigate
AIDS/death, testing the interaction between treatment
class and baseline VL, CD4 count, presence of severe
immune suppression and age. Analyses were adjusted for
demographic (race, HIV exposure group, gender, ethnic
origin, viral hepatitis B and C status, year of starting
ART, cohort and age group), clinical (duration of HIV
infection and nucleoside backbone) and laboratory (CD4
count and VL) parameters, all measured at baseline.
Results
Of 5198 eligible ART-na€ıve persons in RESPOND, 2358
(45.4%) started INSTIs (1342 dolutegravir, 429 raltegravir,
580 elvitegravir and seven bictegravir), 1349 (26.0%) PI/bs
(976 darunavir and 373 atazanavir) and 1491 (28.7%)
NNRTIs (823 efavirenz and 668 rilpivirine). The majority
were male (n = 4248; 81.7%), of white ethnicity (n = 3617;
69.6%), and men who have sex with men (n = 2908;
55.9%). The most commonly used nucleoside backbones
were tenofovir disoproxil fumarate/emtricitabine
(n = 3728; 71.7%) and abacavir/lamivudine (n = 925;
17.8%). Those starting PI/bs were more likely to be female,
to have a higher VL and to have a lower nadir CD4 count.
Those starting INSTIs had started ART more recently.
Overall, 4700 persons (90.4%) had 12 months of fol-
low-up; 2762 [58.8%; 95% confidence interval (CI) 56.9–
60.6%] achieved cTO success (Table 1). The proportion
with cTO success was highest for INSTIs and NNRTIs and
lowest for PI/bs (61.7%, 63.3% and 49.5%, respectively).
After adjustment, those on PI/bs had lower odds of cTO
success [adjusted odds ratio (aOR) 0.74; 95% CI 0.64–
0.87] with no significant differences comparing INSTIs
and NNRTIs. There was no evidence that the differences
in cTO success between INSTIs, PI/bs and NNRTIs differed
according to age group, CD4 count or VL at baseline, or
according to the presence or absence of severe immuno-
suppression (all P-interactions > 0.1). A much higher pro-
portion achieved virological success in the on-treatment
analysis (96.8%; 95% CI 96.2–97.4%; Table 1 and Fig. 1).
After adjustment, those on PI/bs had lower odds of cTO
success (aOR 0.44; 95% CI 0.22–0.89), with nonsignificant
differences comparing INSTIs and NNRTIs. There was no
evidence that the differences in on-treatment virological
success between INSTIs, PI/bs and NNRTIs differed
according to age group, CD4 count or VL at ART initia-
tion, or according to the presence or absence of severe
immunosuppression (all P-interactions > 0.1).
In total, 3979 (76.5%) persons had 12 months of fol-
low-up and a CD4 count measured at 12 months, and
905 (22.7%; 95% CI 21.4–24.0%) achieved immunological
success (Table 1). The proportion with immunological
success was highest for those starting INSTIs (Table 1).
After adjustment, particularly for age and nadir CD4
count, those on NNRTIs had lower odds of immunological
response (aOR 0.67; 95% CI 0.52–0.85), with no statisti-
cally significant differences comparing INSTIs and PI/bs
(Fig. 1). There was no evidence that the differences in
immunological response between INSTIs, PI/bs and
NNRTIs varied according to age group, CD4 count or VL
at ART initiation, or presence or absence of severe
immunosuppression (all P for interactions > 0.1).
A total of 258 persons had a new AIDS diagnosis or
died > 14 days after ART initiation during 15 466 per-
son-years of follow-up (PYFU) (incidence rate 16.7/1000
PYFU; 95% CI 14.6–18.7). Among those with an event,
the median time to event was 4 months [interquartile
range (IQR) 1–15 months]. The most common event was
death (n = 63; 24.4%), followed by pulmonary tuberculo-
sis (n = 28; 10.9%) and non-Hodgkin’s lymphoma
(n = 26; 10.1%). There were no differences in the propor-
tion with VL > 200 copies/mL at event (132/258; 51.2%)
across ART classes (P = 0.028). Those starting INSTIs had
lower CD4 counts at events (median 139 cells/lL) com-
pared to those starting NNRTIs (median 221 cells/lL) and
PI/bs (median 212 cells/lL; P = 0.013). The crude inci-
dence was highest for those starting INSTIs and lowest
for those starting NNRTIs (Table 1). After adjustment,
particularly for age and nadir CD4 count, there were no
significant differences in the incidence of new AIDS diag-
noses or death between ART classes (Fig. 1). Importantly,
this finding was consistent across age groups, CD4 counts
and VLs at baseline, and between those with and without
severe immune suppression (all P for interactions > 0.1).
Results were consistent for cTO and virological success
using a lower limit of detection of 50 copies/mL, when
immunological success was defined as a CD4 count
increase to > 500 cells/lL (baseline CD4 count < 400
cells/lL) or a 25% increase in CD4 count (baseline CD4
count > 400 cells/lL), for cTO, virological and immuno-
logical success at 6 months after starting ART, and for
clinical progression to new AIDS diagnosis/death censor-
ing at first change to regimen started (data not shown).
Discussion
This analysis of ART-na€ıve persons starting contemporary
ART in the large RESPOND cohort collaboration focused
on a composite treatment outcome and immunological
success at 12 months and new AIDS diagnosis or death
occurring more than 14 days after starting ART. While
there were some differences in cTO and immunological
success in favour of INSTIs, findings were consistent
© 2020 The Authors.
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across subgroups defined by age, CD4 count, VL and sev-
ere immune suppression (AIDS or CD4 count ≤ 200 cells/
lL).
We found some evidence that virological treatment
response to INSTIs was better than that to contemporary
PI/bs using both composite outcomes and an on-treat-
ment analysis, consistent with recent meta-analyses
[15,16], open-label studies [17] and findings from obser-
vational studies [9,11,18]. We also found a slightly better
immunological response with INSTIs compared to
NNRTIs, as has been previously shown [6,7,19]. Impor-
tantly, the differences in immunological and virological
responses found when comparing the three antiretroviral
classes were consistent in the key subgroups investigated.
While we adjusted for important confounders, such as
age and nadir CD4 count, we cannot exclude
confounding by indication. We chose a relatively high
CD4 count for immunological response, reflecting the
comparatively high CD4 count nadir in the included indi-
viduals, as well as evidence that the incidence of AIDS
no longer decreases at CD4 counts > 750 cells/lL [14],
but found consistent results in sensitivity analyses using
lower CD4 count increases to define immunological
response.
To our knowledge, we are the first to show no differ-
ences in AIDS or mortality outcomes comparing INSTIs,
PI/bs and NNRTIs, albeit with limited power. We focused
on events occurring > 14 days after ART to reduce the
impact of early events caused by late presentation. The
median time to event remained short, suggesting that
some of the events were caused by uncontrolled HIV
infection and/or late presentation. We focused on AIDS
Table 1 Summary of persons included and outcomes
All INSTIs PI/bs NNRTIs
N (%) N (%) N (%) N (%)
Total 5198 (100) 2358 (45.4) 1349 (26.0) 1491 (28.7)
Characteristics at baseline
HIV VL
≤ 100 000 copies/mL 3285 (63.2) 1417 (60.1) 759 (56.3) 1109 (74.4)
> 100 000 copies/mL 1913 (36.8) 941 (39.9) 590 (43.7) 382 (25.6)
CD4 count
≤ 350 cells/lL 2570 (49.4) 1124 (47.7) 822 (60.9) 624 (41.9)
> 350 cells/lL 2628 (50.6) 1234 (52.3) 527 (39.1) 867 (58.1)
Severe immune suppression*
No 3702 (71.2) 1653 (70.1) 838 (62.1) 1211 (81.2)
Yes 1496 (28.8) 705 (29.9) 511 (37.9) 280 (18.8)
Age
≤ 40 years 2906 (55.9) 1303 (55.3) 763 (56.6) 840 (56.3)
41–50 years 1390 (26.7) 600 (25.4) 369 (27.4) 421 (28.2)
> 50 years 902 (17.4) 455 (19.3) 217 (16.1) 230 (15.4)
Outcomes
(1) cTO success
n (%) with data 4700 (90.4) 1963 (83.2) 1326 (98.3) 1411 (94.6)
n (%) response 2762 (58.8) 1212 (61.7) 657 (49.5) 893 (63.3)
95% CI (56.9-60.6) (59.0-64.5) (45.7-53.4) (60.1-66.4)
(2) On-treatment virological success
n (%) with data 2912 (56.0) 1254 (53.2) 715 (53.0) 943 (63.2)
n (%) response 2819 (96.8) 1233 (98.3) 676 (94.5) 910 (96.5)
95% CI (96.2-97.4) (97.6-99.0) (92.9-96.2) (95.3-97.7)
(3) Immunological success
n (%) with data 3979 (76.5) 1667 (70.7) 1117 (82.8) 1195 (80.1)
n (%) response 905 (22.7) 454 (27.2) 207 (18.5) 244 (20.4)
95% CI (21.4-24.0) (25.1-29.4) (16.3-20.8) (18.1-22.7)
(4) Clinical progression
n (%) with data 5198 (100.0) 2358 (100.0) 1349 (100.0) 1491 (100.0)
Number of events (PYFU) 258 (15 465.8) 106 (5093.0) 92 (5175.9) 60 (5196.9)
Rate/1000 PYFU (16.7) (20.8) (17.8) (11.5)
95% CI (14.6-18.7) (16.9-24.8) (14.1-21.4) (8.6-14.5)
Values are n (%), unless otherwise stated.
CI, confidence interval; cTO, composite treatment outcome; INSTI, integrase strand transfer inhibitor; PI/b, boosted protease inhibitor; NNRTI, nonnucle-
oside reverse transcriptase inhibitor; PYFU, person-years of follow-up. (1) VL < 200 copies/mL, no change in ART regimen and no AIDS or death. Miss-
ing VL = failure. (2) VL < 200 copies/mL and no treatment change; missing VL = excluded. (3) CD4 count > 750 cells/lL if baseline CD4
count < 500 cells/lL or 33% increase if baseline CD4 count > 500 cells/lL. (4) New AIDS event or death > 14 days after baseline; rates per 1000
PYFU.
*AIDS or CD4 count ≤ 200 cells/lL.
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and death to reduce confounding by indication related to
the choice of initial ART in persons with underlying
comorbidities. Of note, our findings were similar across
key subgroups, less often considered particularly in
cohort studies. This finding is of direct clinical relevance
and can be used in routine clinic settings to reassure per-
sons starting ART.
The main limitation of our study is that we cannot rule
out confounding by indication. We were not powered to
look at individual antiretrovirals and it is possible that
results differ within ART classes for specific agents. The
major strengths of this study were the inclusion of rou-
tine clinic populations, inclusion of clinical events as an
endpoint, and the focus on whether results were consis-
tent across key subgroups.
To conclude, differences among ART classes in virolog-
ical, immunological and clinical outcomes in ART-na€ıve
participants were consistent irrespective of age, immune
suppression or VL at ART initiation. While confounding
by indication cannot be excluded, this provides reassur-
ing evidence that such subpopulations will equally bene-
fit from modern ART.
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